The California Biotechnology Foundation is committed to keeping you up to date about COVID-19 testing, treatment and prevention advancements. The following resources track what progress has been made as of September 18, 2020. Notable advancements include:

• Eli Lilly and Amgen have announced a partnership to increase supply of a COVID-19 antibody treatment after it was shown to reduce the need for hospitalization.
• Moderna released details on how they are conducting a late-stage trial of its COVID-19 vaccine while ensuring they will determine safety and efficacy.
• Pfizer’s COVID-19 vaccine could be distributed to Americans before the end of the year if found to be safe and effective by the Food and Drug Administration.

Recent News:

• Lilly and Amgen partner to manufacture potential COVID-19 drugs
  CNBC – September 17, 2020 
  Eli Lilly partnered with Amgen to increase the supply of its experimental COVID-19 antibody treatments after one of Lilly’s drugs was shown to reduce the need for hospitalization.
• Moderna Shares the Blueprint for Its COVID-19 Vaccine Trial
  New York Times – September 17, 2020 
  The biotech company Moderna released a 135-page document that spells out the details of how it is conducting the late-stage trial of its COVID-19 vaccine, and how safety and efficacy will be determined.
• Pharma company drastically boosts its potential COVID-19 vaccine production
  CNN – September 17, 2020 
  German pharmaceutical company BioNTech, which is currently developing a possible vaccine against COVID-19 together with US drug giant Pfizer, announced it was buying a new production plant in order drastically to increase its production capacities.
• Pfizer Says Its COVID-19 Vaccine Is Just the First in a New Wave of Preventives
  Barron’s – September 16, 2020 
  A 44,000-patient trial of the COVID-19 vaccine developed by Pfizer and BioNTech remains on track to deliver results by late October.
• An Experimental Drug Protects COVID-19 Patients, Eli Lilly Claims
  New York Times – September 16, 2020 
  A single infusion of an experimental drug markedly reduced levels of the COVID-19 in newly infected patients and lowered the chances that they would need hospitalization.
• Pfizer COVID-19 vaccine could be given to Americans before the end of the year, CEO says
  CNBC – September 14, 2020 
  Pfizer’s COVID-19 vaccine could be distributed to Americans before the end of the year if found to be safe and effective, CEO Albert Bourla said.
• Eli Lilly’s rheumatoid arthritis drug helps recovery in COVID patients
  CNBC – September 14, 2020 
  Eli Lilly said its rheumatoid arthritis drug baricitinib shortened the time taken to recover from COVID-19 in hospitalized patients when taken in combination with Gilead Sciences’ antiviral remdesivir.
• Gilead CEO: We’re studying new ways to treat COVID-19 with remdesivir outside of the hospital
  CNBC – September 14, 2020 
  Gilead Sciences CEO Daniel O’Day told CNBC that the company is continuing to study new ways to use its COVID-19 treatment remdesivir on patients, including potentially outside of the hospital altogether.
• Pfizer proposes expanding COVID-19 vaccine trial to include more diversity as the race for a vaccine continues
  CNN – September 13, 2020 
  Pfizer and BioNTech announced they proposed expanding Phase 3 clinical trials to include 44,000 participants and more diverse patient populations, including people as young as 16.